Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
Leuk Res. 2012 Dec;36(12):1517-20. doi: 10.1016/j.leukres.2012.08.019. Epub 2012 Aug 30.
We analyzed the outcome of 46 patients with acute lymphoblastic leukemia (ALL) who relapsed following treatment with a pediatric-based protocol; 34 received intensive re-induction chemotherapy, with a CR2 rate of 62%, median overall survival (OS) 7.8 months, median relapse-free survival 5.2 months and one year OS 19%. Allogeneic HSCT was performed in 8 patients in CR2/3, with a median OS 2.2 months. OS was superior in patients who relapsed after completion of chemotherapy, compared to those relapsing on treatment. The outcome of adult ALL relapsing after treatment was therefore poor, and novel salvage strategies are needed to improve outcomes.
我们分析了 46 例接受基于儿科方案治疗后复发的急性淋巴细胞白血病（ALL）患者的结局；34 例患者接受了强化再诱导化疗，CR2 率为 62%，中位总生存期（OS）为 7.8 个月，中位无复发生存期为 5.2 个月，1 年 OS 为 19%。8 例 CR2/3 的患者进行了异基因 HSCT，中位 OS 为 2.2 个月。与治疗中复发的患者相比，化疗完成后复发的患者的 OS 更好。因此，成人 ALL 治疗后复发的结局较差，需要新的挽救策略来改善结局。
